Recent Security Class Actions

Fate Therapeutics Inc. Common Stock (NASDAQ: FATE)

Company Name:Fate Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: FATE
Class Period Start:08/05/2020
Class Period End (inclusive):01/05/2023
Filing Deadline:03/21/2023

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors; (ii) accordingly, certain of the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement’s on Fate’s long-term clinical and commercial profitability; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.